HM3A joins Vivactis Group


Vivactis-Newton 21 Europe and the Prof. dr. Dr. Alain de Wever , Dr. Christian Huyghe , Dr. Marc Czarka , Dr. Arié Kupperberg and Pharmacist Jean-Antoine the Muylder have decided to bundle their skills. The Vivactis-Newton 21 group is already a leader in services and consulting for the health market and HM3A sprl , from now on HM3A-VIVACTIS , specialized for more than 10 years in Market Access, allows us to to offer a comprehensive set of services to Vivactis Group customers and to the market in general with the ability to build and implement effective, innovative and consistent strategies.

About HM3A

HM3A, the consulting company specialiced in “Market Access” for pharmaceutical and medical devices and also in procedures relating to the relevant authorities and institutions (European Medicines Agency, Notified bodies, ETS settings ), offers the following services:

  • Strategic market access and marketing advice
  • Strategy and tactics for price and reimbursement
  • Development of value propositions
  • Payer Research
  • “Value dossier ” and submitting dossiers for Health Technology Assessment
  • Early access to the market
  • Regulatory, Governmental and Public Affairs
  • Due diligence with regard to Market Access
  • Market Access Audits

 

” We are proud to be a member of an international group that will strengthen our Market Access activities in the BENELUX; with expansion possibilities in the European Union. Our years of experience will be an important asset in serving a larger market through our integration into a versatile group in the healthcare sector. By the time EMA leave London and move to Amsterdam and when local agencies must reorganise in this new environment, we are happy to become a member from the group Vivactis and to expand our range of services in BENELUX and the European markets andfor both medicines and medical devices. ” explain the founders of HM3A.

The acquisition of HM3A strengthens the Leadership position of the Vivactis Group in the health market in Belgium , as it is already the case in France, Spain and Switzerland, …